• Nature Chem. Biol. 15 (6), 565-74 (2019), “Substrate-selective inhibitors that reprogram the activity of Insulin-Degrading Enzyme” Maianti JP, Tan GA, Vetere A, Welsh AJ, Wagner BK, Seeliger MA, and Liu DR.

  • Nature, 511, 94-8 (2014), “Anti-diabetic activity of Insulin-Degrading Enzyme inhibitors mediated by multiple hormones” Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du X-Q, Leissring MA, Tang W-J, Charron MJ, Seeliger MA, Saghatelian A, and Liu DR.

* This work was highlighted in The Boston Globe, Nature News, Nature Endocrinology, Cell Metabolism, ACS ChemBio, C&EN News, MIT Technology Review, Healthline,, and other science news outlets. The IDE inhibitor (6bK) is offered to the scientific community by R&D/Tocris and Phoenix Peptides.

  • ACS Chemical Biology, 9 (9), 2067-73 (2014), “Toxicity modulation, resistance enzyme evasion, and A-site X-ray structure of broad-spectrum antibacterial Neomycin analogs” Maianti JP, Kanazawa H, Dozzo P, Matias RD, Feeney LA, Armstrong ES, Kane TR, Gliedt MJ, Goldblum A, Linsell MS, Aggen JB, Kondo J, and Hanessian S.

* This work was featured in C&EN News and the ACS Chemical Biology podcast interview of Sept. 2014.

  • Org. Lett. 13 (24), 6476-9 (2011), “Hybrid aminoglycoside antibiotics via Tsuji Palladium-catalyzed allylic deoxygenation” Hanessian S, Maianti JP, Matias RD, Feeney LA, and Armstrong ES.


  • Nature Biotechnol. 36 (9), 843-6 (2018), “Improving Cytidine and Adenine Base Editors by expression optimization and ancestral reconstruction” Koblan LW, Doman JL, Wilson C, Levy JM, Tay T, Newby GA, Maianti JP, Raguram A, and Liu DR.

  • Nature Chem. 10 (7), 704-14 (2018), “Second-generation DNA-templated macrocycle libraries for the discovery of bioactive small molecules” Usanov DL, Chan AI, Maianti JP, and Liu DR.

  • Org. Lett. 11 (2), 429-32 (2009), “Synthesis and comparative antibacterial activity of Verdamicin C2 and C2a – A new oxidation of primary allylic azides in dihydro[2H]pyrans” Szychowski J, Maianti JP, and Hanessian S.

  • ACS Med. Chem. Lett. 2 (12), 924-8 (2011), “Toward overcoming Staphylococcus aureus Aminoglycoside resistance mechanisms with a functionally designed Neomycin analogue” Giguère A, Grzyb J, Maianti JP, Saavedra OM, Aggen JB, Linsell MS, Goldblum AA, Hildebrandt DJ, Kane TR, Dozzo P, Gliedt MJ, Matias RD, Feeney LA, Armstrong ES, and Hanessian S.

  • ChemMedChem 8 (5), 733-9 (2012), “Crystal structures of a bioactive 6′-hydroxy variant of Sisomicin bound to the bacterial and protozoal ribosomal decoding sites” Kondo J, Koganei M, Maianti JP, Ly VL, and Hanessian S.

  • Chem. Sci. 5, 4621-32 (2014), “Synthesis, broad spectrum antibacterial activity, and X-ray co-crystal structure of the decoding bacterial ribosomal A-site with 4′-deoxy-4′-fluoro neomycin analogs”, Saavedra OM, Vilchis-Reyes MA, Maianti JP, Kanazawa H, Dozzo P, Matias RD, Serio A, Kondo J, and Hanessian S.

  • Apoptosis 21, 866-72 (2016), “The fungicide Mancozeb induces metacaspase-dependent apoptotic cell death in Saccharomyces cerevisiae” Scariot FJ, Jahn LM, Maianti JP, Delamare APL, and Echeverrigaray S.

  • ChemMedChem 13 (15), 1541-8 (2018), “Structure‐based design of a eukaryote‐selective antiprotozoal fluorinated aminoglycoside” Kanazawa H, Saavedra OM, Maianti JP, Young SA, Izquierdo L, Smith TK, Hanessian S, and Kondo J.


"Assay for Exo-Site Binding Molecules” WO/2018/081534

“DNA-Templated Macrocycle Library” WO/2019/168654

“Substrate Selective Inhibitors of Insulin-Degrading Enzyme (IDE) and Uses Thereof” WO/2016/172631

“Assay for Insulin-Degrading Enzyme (IDE) Inhibitors” WO/2015/069876

“Macrocyclic Insulin-Degrading Enzyme (IDE) Inhibitors and Uses Thereof” WO/2013/006451

“Antibacterial Aminoglycoside Analogs” Aggen et al. WO/2011/044498

“Antibacterial Aminoglycoside Analogs” Maianti et al. WO/2010/030704

“Suppression of Pain by Gene Editing” WO/2018/165504

“Cancer Vaccine” WO/2018/165631

“Incorporation of Unnatural Amino Acids into Proteins Using Base Editing” WO/2018/039438

“Editing of CCR5 Receptor Gene to Protect Against HIV Infection” WO/2018/119359

“Gene Editing of PCSK9” WO/2018/119354